A Double‐Blind, Randomized, Comparative Study of Two Type A Botulinum Toxins in the Treatment of Primary Axillary Hyperhidrosis

Talarico-Filho, Sérgio; Nascimento, Maurício Mendonça do; Macedo, Fernando S.; Pecora, Carla de Sanctis

doi:10.1111/j.1524-4725.2006.32331.x

Cited by 66 publications

(48 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Finally, Talarico-Filho and colleagues 40 found no difference in efficacy at a 3:1 ratio in the treatment of axillary hyperhidrosis in 10 patients.…”

Section: Hyperhidrosismentioning

confidence: 96%

“…This might not be a drug-related effect but could instead be due to variability of the clinical scoring method used, and this weakens the conclusions of Lowe and colleagues substantially. 23 According to a Phase II Food and Drug Administration trial of Dysport in the treatment of glabellar lines, a dosage of as low as 20 U is effective in most cases, supporting a unit equivalence of 2.5:1. , Karsai et al 21 , Monheit et al 24 , Ascher et al 26 , Rzany et al 29 , Ranoux et al 31 , Odergren et al 33 , Poewe et al 34 , Simonetta-Moreau et al 38 , Talarico-Filho et al 40 , Wohlfarth et al 43 IIa SR of cohort studies (CS) with homogeneity Sesardic et al 9 , Poewe, 32 Rosales et al 45 IIb Individual CS or low-quality RCT Bihari, 16 Lowe et al 22 , Brisinda et al 35 , Sampaio et al 36 , Nü Xgens and Roggenkä mper, 37 Trindade de Almeida et al 39 , Hexsel, 41 de Almeida et al 42 IIc ''Outcomes'' research Marchetti et al 17 , Heckmann and Schö n-Hupka, 25 Van den Bergh and Lison, 44 Rosales et al 45 V Expert opinion Hambleton and Pickett, 7 Rzany and Zielke, 11 Sommer et al 20 SR, systematic review; RCT, randomized controlled trial; CI, confidence interval; CS, cohort study.…”

Section: Cosmetic Applications (Hyperfunctional Lines)mentioning

confidence: 99%

See 1 more Smart Citation

Current Evidence on the Unit Equivalence of Different Botulinum Neurotoxin A Formulations and Recommendations for Clinical Practice in Dermatology

Karsai

Raulin

2009

Dermatologic Surgery

View full text Add to dashboard Cite

BACKGROUND The unit equivalence between the two main Botulinum neurotoxin A (BoNTA) preparations, Dysport (Ipsen Ltd., Slough, Berkshire, UK) and BOTOX (Allergan Inc., Irvine, CA), is a matter of discussion. The UK assay used to test Dysport is more sensitive than the U.S. assay used for BOTOX, resulting in a different efficacy per unit in both formulations. Ratios ranging from 6:1 to 1:1 can be found in the literature, but the more recently published literature suggests that 1 unit of BOTOX is equivalent to approximately 2 to 4 units of Dysport (ratio 2:1–4:1). OBJECTIVE Because the number of BoNTA treatments is constantly increasing, these differences warrant a systematic review of published evidence about the unit equivalence of UK and U.S. formulations. METHODS The review is based on a detailed literature research in all relevant databases (MEDLINE, PubMed, Cochrane Library, specialist textbooks). RESULTS The present review supports the recent assumption that dose ratios of less than 3:1 (e.g., 2.5:1 or even 2:1) between Dysport and BOTOX are probably more suitable. CONCLUSIONS The current evidence is still insufficient, and further investigation of lower dose ratios is recommended.

show abstract

“…Finally, Talarico-Filho and colleagues 40 found no difference in efficacy at a 3:1 ratio in the treatment of axillary hyperhidrosis in 10 patients.…”

Section: Hyperhidrosismentioning

confidence: 96%

Section: Cosmetic Applications (Hyperfunctional Lines)mentioning

confidence: 99%

Current Evidence on the Unit Equivalence of Different Botulinum Neurotoxin A Formulations and Recommendations for Clinical Practice in Dermatology

Karsai

Raulin

2009

Dermatologic Surgery

View full text Add to dashboard Cite

show abstract

“…3,18 Em teoria, a toxina botulínica tem potenciais vantagens quando comparada a analgésicos orais, seja por sua longa duração de ação (aproximadamente três meses), pela facilidade de ser administrada diretamente no ponto doloroso, por sua excelente tolerabilidade, seja por seu perfil de segurança e ausência de efeitos sistêmicos. 25 …”

Section: Técnica De Aplicaçãounclassified

Toxina botulínica: uma nova opção para o tratamento da neuralgia pós-herpética?

Talarico

2014

Revista Hospital Universitário Pedro Ernesto

View full text Add to dashboard Cite

ResumoA dor neuropática pode ocorrer após injúria do sistema nervoso central ou periférico, gerando dor espontânea, alodínea e hiperalgesia. Uma das principais causas de dor neuropática é a neuralgia pós-herpética. Sua incidência aumenta em pacientes com idade mais avançada, o que dificulta ainda mais o tratamento, muitas vezes limitado por seus efeitos colaterais, principalmente cognitivos. A combinação de tratamentos é prática clínica comum e novas modalidades terapêuticas vêm sendo aplicadas para aliviar essa condição. A toxina botulínica tipo A tem sido usada para diversos quadros clínicos associados à hiperatividade muscular, como distonia cervical. Recentemente, foram propostos mecanismos analgésicos independentes da contração muscular, ainda pouco conhecidos.Descritores: Neuralgia; Neuralgia pós-herpética; Toxinas botulínicas tipo A. AbstractNeuropathic pain can occur after injury to the peripheral and/or central nervous system, resulting in spontaneous pain, allodynia and hyperalgesia. One of the main causes of neuropathic pain is post-herpetic neuralgia. It occurs increasingly with age and that makes the treatment even more complicated due to the limitation caused by cognitive adverse effects. Combining therapies with different mechanisms of action is usual in clinical practice and new procedures are considered to treat this condition. Botulinum toxin type A has been used to treat certain disorders related to muscle overactivity. Not well known analgesic mechanisms have been proposed recently, independent of the muscle contraction.Keywords: Neuralgia; Neuralgia, postherpetic; Botulinum toxins, type A. ResumenEl dolor neuropático puede darse después del daño al sistema nervioso central o periférico, provocando dolor espontáneo alodinia y hiperalgesia. Una de las principales causas del dolor neuropático es la neuralgia postherpética. Su incidencia aumenta en pacientes de edad avanzada, lo que dificulta todavía más el tratamiento, muchas veces limitado por sus efectos colaterales, principalmente cognitivos. La combinación de tratamientos es práctica clínica común y se vienen aplicando nuevas modalidades terapeúticas para aliviar esta situación. La toxina botulínica tipo A ha sido usada en diversos cuadros clínicos asociados a la hiperactividad muscular, como distonía cervical. Recientemente, fueron propuestos mecanismos analgésicos independientes de la contracción muscular, todavía poco conocidos.Palabras clave: Neuralgia; Neuralgia posherpética; Toxinas botulínicas tipo A.* Endereço para correspondência: Rua Maestro Francisco Braga, 175, ap. 101 Rio de Janeiro, RJ, Brasil. CEP: 22041-070.

show abstract

“…Data on permanence of the effects are rather divergent in the literature but fall in the range of 7 to over 12 months after which the sweat glands activity is gradually restored and the treatment must be performed again (14,43).…”

Section: Botulinum Toxin Therapymentioning

confidence: 99%

“…Talarico-Filho et al (43) have conducted research on the percentage of people whose treatment was successful. Reduction by 50% of secreted sweat after the treatment in comparison to measurements performed before botulinum toxin type A has been treated as objective success.…”

Section: Botulinum Toxin Therapymentioning

confidence: 99%

Diagnosis and Treatment of Primary Hyperhidrosis

Stefaniak¹,

Dobosz²,

Kaczor³

et al. 2013

Polish Journal of Surgery

View full text Add to dashboard Cite

A Double‐Blind, Randomized, Comparative Study of Two Type A Botulinum Toxins in the Treatment of Primary Axillary Hyperhidrosis

Abstract: BOTOX and Dysport presented similar levels of safety and efficacy in the treatment of primary axillary hyperhidrosis when a conversion factor of 1:3 was used.

Cited by 66 publications

References 23 publications

Current Evidence on the Unit Equivalence of Different Botulinum Neurotoxin A Formulations and Recommendations for Clinical Practice in Dermatology

Current Evidence on the Unit Equivalence of Different Botulinum Neurotoxin A Formulations and Recommendations for Clinical Practice in Dermatology

Toxina botulínica: uma nova opção para o tratamento da neuralgia pós-herpética?

Diagnosis and Treatment of Primary Hyperhidrosis

Contact Info

Product

Resources

About